Equillium, Inc. (NASDAQ:EQ) Expected to Post Earnings of -$0.38 Per Share

Wall Street brokerages forecast that Equillium, Inc. (NASDAQ:EQGet Rating) will announce earnings per share (EPS) of ($0.38) for the current quarter, Zacks reports. Zero analysts have made estimates for Equillium’s earnings. The lowest EPS estimate is ($0.42) and the highest is ($0.35). Equillium reported earnings of ($0.31) per share during the same quarter last year, which would indicate a negative year over year growth rate of 22.6%. The firm is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Equillium will report full-year earnings of ($1.39) per share for the current year, with EPS estimates ranging from ($1.77) to ($1.10). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.38) to ($1.03). Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Equillium.

Equillium (NASDAQ:EQGet Rating) last announced its quarterly earnings data on Wednesday, March 23rd. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02).

EQ has been the topic of several analyst reports. Zacks Investment Research lowered shares of Equillium from a “buy” rating to a “hold” rating in a report on Thursday, May 12th. HC Wainwright increased their target price on shares of Equillium from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, March 24th. Stifel Nicolaus reiterated a “buy” rating and issued a $12.00 target price on shares of Equillium in a report on Friday, March 25th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Equillium in a report on Monday, May 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $11.50.

Shares of NASDAQ EQ opened at $2.48 on Wednesday. The company’s 50 day simple moving average is $2.95 and its 200 day simple moving average is $3.90. Equillium has a fifty-two week low of $2.12 and a fifty-two week high of $7.75. The firm has a market capitalization of $85.01 million, a P/E ratio of -1.13 and a beta of 1.31. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.50 and a quick ratio of 5.50.

In related news, CFO Jason A. Keyes sold 8,000 shares of the firm’s stock in a transaction on Monday, April 4th. The shares were sold at an average price of $3.18, for a total value of $25,440.00. Following the completion of the transaction, the chief financial officer now owns 23,296 shares of the company’s stock, valued at $74,081.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 28.50% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in shares of Equillium in the 1st quarter valued at about $47,000. Cota Capital Management LLC bought a new position in shares of Equillium in the 1st quarter valued at about $1,771,000. State Street Corp grew its position in shares of Equillium by 13.2% in the 1st quarter. State Street Corp now owns 56,220 shares of the company’s stock valued at $177,000 after acquiring an additional 6,564 shares during the period. Decheng Capital Management III Cayman LLC bought a new position in shares of Equillium in the 1st quarter valued at about $14,009,000. Finally, Victory Capital Management Inc. lifted its stake in shares of Equillium by 8.2% during the 1st quarter. Victory Capital Management Inc. now owns 3,597,799 shares of the company’s stock worth $11,333,000 after buying an additional 272,749 shares during the last quarter. 23.32% of the stock is owned by institutional investors and hedge funds.

About Equillium (Get Rating)

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis.

Further Reading

Get a free copy of the Zacks research report on Equillium (EQ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Equillium (NASDAQ:EQ)

Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.